Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04490460
Recruitment Status : Enrolling by invitation
First Posted : July 29, 2020
Last Update Posted : July 29, 2020
Sponsor:
Collaborator:
Pendulum Therapeutics
Information provided by (Responsible Party):
Eden Miller, Diabetes and Obesity Care

Brief Summary:
Evaluation of the safety and effects on glycemic control of medical food formulation WBF-0031 in subjects with abnormal glucose control.

Condition or disease Intervention/treatment Phase
Abnormal Glucose Tolerance Dietary Supplement: WBF-0031 Not Applicable

Detailed Description:

The current study aims to investigate if altering the microbiome though Pendulum Glucose Control supplementation can have implications aimed at maintaining normal blood glucose levels that are critical for preventing diabetes and its metabolic complications. The experimental design consists of two-12 week treatment periods in subjects with prediabetes, as defined by the National Diabetes Prevention Program (DPP) criteria.

The first study period of 12 weeks will be double-blinded, placebo-controlled. The Pendulum Glucose control and placebo will be in a capsule form and identical in appearance, and dispensed to each participant according to the randomization schedule in the first 12 weeks. All subjects will receive the active product (Pendulum Glucose Control) in the second, subsequent 12 week period.

Fasting total cholesterol, triglycerides, LDL, and HDL cholesterol, Fasting insulin and Glucose, High sensitivity C Reactive Protein (hsCRP), Chemistry 14, and HbA1c will be obtained at baseline, and during first and second study period, as well as vital signs of weight, BP, and waist circumference.

In addition, CGM (Abbott System Freestyle Libre Pro) data collection will be done three times during the study as noted in Schedule of Events. Baseline Blinded CGM will be performed for approximately 14 days prior to starting the intervention with Pendulum Glucose Control. Second Blinded CGM period for approximately 14 days will occur mid-way through the intervention (weeks 5 and 6) and a third period of Blinded CGM wear will occur during the last 2 weeks of the intervention (weeks 11 and 12). During the Baseline, study period one and period 2 a mixed meal tolerance consisting of 2 Boost Shakes will be given on day 5 of each sensor wear.

At the completion of the study, analysis of the vital signs, laboratory values, CGM data for average glucose, standard deviation, TIR (time in range), as well as glycemic results of MMT for each time interval; baseline, study period one, and two.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Balanced randomization first arm, formulation WBF-0031 and placebo. Second arm all subjects formulation WBF-0031.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Study product was provided for each arm in identical capsules.
Primary Purpose: Treatment
Official Title: Evaluation of the Safety and Effects on Glycemic Control of Medical Food Formulation WBF-0031 in Subjects With Abnormal Glucose Tolerance
Actual Study Start Date : June 1, 2020
Estimated Primary Completion Date : February 1, 2021
Estimated Study Completion Date : February 28, 2021

Arm Intervention/treatment
Placebo Comparator: First 12 Weeks
1 capsule administered twice daily with morning and evening meal for 12 weeks. Double blind 50% Placebo capsules identical to those containing WB-0031 and 50% WB-0031
Dietary Supplement: WBF-0031
Medical food formulation WBF-0031

Active Comparator: Second 12 Weeks
1 capsule administered twice daily with morning and evening meal for 12 weeks. All participants receiving WB-0031.
Dietary Supplement: WBF-0031
Medical food formulation WBF-0031




Primary Outcome Measures :
  1. Safety Assessment of Adverse Events [ Time Frame: 30 weeks ]
    Safety assessed via spontaneous adverse events reported during the study period and changes in chemistry 14 panel

  2. Time spent in target blood glucose [ Time Frame: Three 14 day intervals ]
    Difference in daily glucose levels as measured by the amount of time spent in target blood glucose for each CGM wear period. Adjustable glucose thresholds will be set as follows:<60 mg/dL, <70 mg/dL, >140 mg/dL, >180 mg/dL and >240 mg/dL. The percent of values above, below, and between these points will be calculated.


Secondary Outcome Measures :
  1. Total Glucose Area Under the Curve (AUC) from baseline [ Time Frame: 24 weeks ]
    Twelve and 24 week difference from baseline in total Glucose AUC during a standard Meal Tolerance Test (MMT)

  2. Incremental Glucose Area Under the Curve (AUC) from baseline [ Time Frame: 24 weeks ]
    Twelve and 24 week difference from baseline in incremental Glucose AUC during a standard Meal Tolerance Test (MMT)

  3. Glucose peaks [ Time Frame: 30 weeks ]
    Mean and standard deviation of post-prandial peak glucose and time to peak for each meal

  4. A1c [ Time Frame: Week 0, Week 12, Week 24 ]
    Improvement in A1c measured as a change in A1c levels from baseline at 12 and 24 weeks. Subjects enrolled in the study will have fasting A1c measurements at the time of enrollment and weeks, 0, 12 and 24 weeks.


Other Outcome Measures:
  1. Questionnaire [ Time Frame: Week 0, Week 12, Week 24 ]
    Quality of life questionnaire responses measured at 0, 12 and 24 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Between 18-80 years of age
  2. BMI < 45 kg/m2
  3. Eligible based on a recent (within the past year) blood test meeting one of these specifications:

    1. Fasting glucose of 100 to 125 mg/dl
    2. Plasma glucose measured 2 hours after a 75-gram glucose load of 140 to 199 mg/dl
    3. A1c of 5.7 to 6.4%
    4. Clinically diagnosed gestational diabetes mellitus (GDM) during a previous pregnancy (may be self-reported)
  4. Willing to comply with study requirements
  5. Provide written informed consent

Exclusion Criteria:

  1. Known diagnosis of diabetes / taking any medication for the treatment of diabetes including the off-label use of a GLP-1 receptor agonist, SGLT-2, or metformin) within the last 3 months for weight loss.
  2. Active participation in another lifestyle or behavior change education or research program (DPP or weight loss program)
  3. Current treatment with systemic corticosteroids (topical and nasal steroids are allowed)
  4. Subjects who have received an antibiotic, antifungal, antiparasitic, or antiviral treatment within 30 days prior to study entry
  5. Pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04490460


Locations
Layout table for location information
United States, Oregon
Diabetes and Obesity Care
Bend, Oregon, United States, 97703
Sponsors and Collaborators
Eden Miller
Pendulum Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Eden Miller, D.O. Diabetes and Obesity Care
Layout table for additonal information
Responsible Party: Eden Miller, Principal Investigator, Diabetes and Obesity Care
ClinicalTrials.gov Identifier: NCT04490460    
Other Study ID Numbers: WB01-501
First Posted: July 29, 2020    Key Record Dates
Last Update Posted: July 29, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glucose Intolerance
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases